Panobacumab
Modify Date: 2024-01-03 07:41:23
Panobacumab structure
|
Common Name | Panobacumab | ||
|---|---|---|---|---|
| CAS Number | 885053-97-4 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PanobacumabPanobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa[1]. |
| Name | Panobacumab |
|---|
| Description | Panobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Panobacumab (KBPA101) strongly binds to 18 of 20 clinical O11 isolates, functional avidity of KBPA101 to O11 LPS determined by inhibition ELISA is 5.81×107 M-1± 2.8×107 M-1[1]. Panobacumab (KBPA101) (0.0001-100 ng/mL; 2 h) specifically mediates complement-dependent opsonophagocytosis of P. aeruginosa serotype O11 with an IC50 of 0.16 ng/mL[1]. Panobacumab (KBPA101) (0.1-10 ng/mL) shows direct complement-dependent killing of P. aeruginosa serotype O11 cells in a dose-dependent manner[1]. |
| In Vivo | Panobacumab (KBPA101) (1-4 mg/kg; i.v.; once) protects mice from systemic infection with P. aeruginosa serotype O11 in a murine burn wound model[1]. Panobacumab (KBPA101) (0.005-0.4 mg/kg; i.v.; once) protects mice from local lung infection with P. aeruginosa serotype O11 in an acute lung infection model[1]. Animal Model: Female NMRI mice, murine burn wound model[1] Dosage: 1, 2, or 4 mg/kg Administration: Intravenous injection, single dose Result: Significantly reduced mortality compared to untreated control animals administered either immediately or 4 h postchallenge. Animal Model: BALB/c mice, acute lung infection model[1] Dosage: 0.005 to 0.4 mg/kg Administration: Intravenous injection, single dose Result: Led to rapid clearance of P. aeruginosa from the lung, completely cleared systemic P. aeruginosa from the spleen, whereas live bacteria were still present in untreated mice at 48 h postchallenge, showed milder macroscopic lung pathology at 6 and 24 h after infection. |
| References |
| No Any Chemical & Physical Properties |